MSD has acquired US cancer therapeutics developer Modifi Biosciences, a Yale University spinout, enhancing its portfolio with preclinical compounds designed to target DNA repair defects in hard-to-treat cancers.
MSD has acquired all outstanding shares of Modifi Biosciences through a subsidiary for an upfront payment of $30m. The deal also includes potential milestone payments of up to $1.3bn for Modifi’s shareholders.
Modifi Biosciences co-founder Ranjit Bindra stated: “In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumours.
“We are honoured to have Merck recognise the potential of our science, and as an oncology company, they are perfectly positioned to advance our innovations through clinical trials and commercialisation.”
The company’s research, initially published in Science [the peer-reviewed academic journal of the American Association for the Advancement of Science] in 2022, has shown preclinical data across various tumour models, including patient-derived xenograft glioma models.
MSD research laboratories discovery oncology vice-president Dr David Weinstock stated: “DNA repair defects are a frequent hallmark of tumour cells and a major cause of resistance to cancer therapy.
“The talented Modifi Biosciences team has developed an innovative approach that we believe has potential for treating some of the most refractory cancer types”.
Modifi Biosciences co-founder Seth Herzon stated: “We designed our small molecules to have the ability to uniquely overcome clinical resistance mechanisms that have been known for decades but until now have been non-actionable. Additionally, we created the molecules in a manner which allows them to be rapidly progressed from bench to bedside.”
The technology developed by Modifi Biosciences avoids traditional methods that indirectly target proteins in cancer cells. It demonstrated anti-tumour activity in laboratory research, inducing irreparable DNA modifications in cancer cells while sparing healthy tissue.
Source: pharmaceutical-technology.com
With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in particular—the Tokyo-based drugmaker is following in the footsteps of several of its peers with a deal to split from its consumer health business.
Lonza Capsugel is launching UC-Flex, a premium collagen and calcium carbonate blend for pet joint health, at Interzoo 2026. The ingredient is backed by twenty years of research and provides a science-validated dose of collagen to improve mobility in dogs. This product addresses a growing market trend, as global demand for functional pet foods and collagen-based launches continues to rise.
Stryker, a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease.
